TY - JOUR
T1 - Chapter 1
T2 - Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022
AU - Muto, Satoru
AU - Matsubara, Takeshi
AU - Inoue, Takamitsu
AU - Kitamura, Hiroshi
AU - Yamamoto, Kazuhiro
AU - Ishii, Taisuke
AU - Yazawa, Masahiko
AU - Yamamoto, Ryohei
AU - Okada, Naoto
AU - Mori, Kiyoshi
AU - Yamada, Hiroyuki
AU - Kuwabara, Takashige
AU - Yonezawa, Atsushi
AU - Fujimaru, Takuya
AU - Kawano, Haruna
AU - Yokoi, Hideki
AU - Doi, Kent
AU - Hoshino, Junichi
AU - Yanagita, Motoko
N1 - Publisher Copyright:
© 2023, The Author(s) under exclusive licence to Japan Society of Clinical Oncology.
PY - 2023/10
Y1 - 2023/10
N2 - The prevalence of CKD may be higher in patients with cancer than in those without due to the addition of cancer-specific risk factors to those already present for CKD. In this review, we describe the evaluation of kidney function in patients undergoing anticancer drug therapy. When anticancer drug therapy is administered, kidney function is evaluated to (1) set the dose of renally excretable drugs, (2) detect kidney disease associated with the cancer and its treatment, and (3) obtain baseline values for long-term monitoring. Owing to some requirements for use in clinical practice, a GFR estimation method such as the Cockcroft–Gault, MDRD, CKD-EPI, and the Japanese Society of Nephrology’s GFR estimation formula has been developed that is simple, inexpensive, and provides rapid results. However, an important clinical question is whether they can be used as a method of GFR evaluation in patients with cancer. When designing a drug dosing regimen in consideration of kidney function, it is important to make a comprehensive judgment, recognizing that there are limitations regardless of which estimation formula is used or if GFR is directly measured. Although CTCAEs are commonly used as criteria for evaluating kidney disease-related adverse events that occur during anticancer drug therapy, a specialized approach using KDIGO criteria or other criteria is required when nephrologists intervene in treatment. Each drug is associated with the different disorders related to the kidney. And various risk factors for kidney disease associated with each anticancer drug therapy.
AB - The prevalence of CKD may be higher in patients with cancer than in those without due to the addition of cancer-specific risk factors to those already present for CKD. In this review, we describe the evaluation of kidney function in patients undergoing anticancer drug therapy. When anticancer drug therapy is administered, kidney function is evaluated to (1) set the dose of renally excretable drugs, (2) detect kidney disease associated with the cancer and its treatment, and (3) obtain baseline values for long-term monitoring. Owing to some requirements for use in clinical practice, a GFR estimation method such as the Cockcroft–Gault, MDRD, CKD-EPI, and the Japanese Society of Nephrology’s GFR estimation formula has been developed that is simple, inexpensive, and provides rapid results. However, an important clinical question is whether they can be used as a method of GFR evaluation in patients with cancer. When designing a drug dosing regimen in consideration of kidney function, it is important to make a comprehensive judgment, recognizing that there are limitations regardless of which estimation formula is used or if GFR is directly measured. Although CTCAEs are commonly used as criteria for evaluating kidney disease-related adverse events that occur during anticancer drug therapy, a specialized approach using KDIGO criteria or other criteria is required when nephrologists intervene in treatment. Each drug is associated with the different disorders related to the kidney. And various risk factors for kidney disease associated with each anticancer drug therapy.
KW - Acute kidney injury
KW - Cancer pharmacology
KW - Glomerular filtration rate
KW - Kidney function
UR - http://www.scopus.com/inward/record.url?scp=85163668150&partnerID=8YFLogxK
U2 - 10.1007/s10147-023-02372-4
DO - 10.1007/s10147-023-02372-4
M3 - 学術論文
C2 - 37382749
AN - SCOPUS:85163668150
SN - 1341-9625
VL - 28
SP - 1259
EP - 1297
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 10
ER -